Sen. Charles Schumer of New York noted that the FDA's own expert panel recommended the reclassification more than nine months ago.
"Each day that passes means rising abuse, and even death, at the hands of hydrocodone-based drugs," Schumer said in a statement.
Still, Thursday's action immediately sparked criticism from some professional groups that said that the tighter restrictions could have unintended consequences, such as burdening health care workers and patients.
"The FDA's reported decision will likely pose significant hardships for many patients and delay relief for vulnerable patients with legitimate chronic pain, especially those in nursing home and long-term care," said Kevin Schweers, a spokesman for the National Community Pharmacists Association.
- USDA Preempts Congress, Enacts Online Pet-Dealing Rules
- Blumenthal Urges Ban on Electronic Cigarette Flavors, Online Sales
- Health Buzz: FDA Recalls Products from a Compounding Pharmacy
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.